Table 2.
Final meta-analyses, excluding studies with possibly considerable false resistance in the reference assaya
| Assay category | No. of data sets | No. of resistant strainsb | No. of susceptible strainsb | Mean value (95% CI) |
Funnel plot asymmetry (P value) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Positive LR | Negative LR | DOR | |||||
| PCR-DNA sequencing | 20 | 715 | 877 | 92 (87–95) | 93 (88–97) | 13.8 (7.0–27.3) | 0.09 (0.05–0.14) | 158 (68–364) | 0.07 |
| Molecular assaysc | 5 | 185 | 381 | 98 (93–100) | 96 (87–99) | 27.7 (6.6–116.4) | 0.02 (0.01–0.07) | 1,438 (202–10,230) | 0.27 |
| Wayne assay | 27 | 912 | 1,802 | 91 (87–94) | 97 (94–98) | 27.3 (14.4–51.7) | 0.09 (0.06–0.14) | 296 (138–635) | 0.03 |
a
CI, confidence interval; DOR, diagnostic odds ratio; LR, likelihood ratio.
b
Based on standard phenotypic drug susceptibility testing.
c
Comprises line probe assay, microarray, branch migration inhibition, and denaturing gradient gel electrophoresis.